Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT05882253
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) — OTHER
    An advanced imaging software that supports improved prostate cancer detection and diagnosis

Study Details

The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.

Key Dates

Start date
Dec 4, 2023
Status verified
Jul 2025
Primary completion
Dec 31, 2027
Completion
Apr 30, 2028

Study Design

Enrollment
225 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: MRI imaging using Siemens MRI
    Participants enrolled will undergo routine Magnetic Resonance Imaging (MRI) to obtain Restricted Spectrum Mapping (RSM). These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
  • Other: MRI imaging using Phillips MRI
    Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
  • Other: MRI imaging using General Electric (GE) MRI
    Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.

Primary Outcome Measure

RSM mapping value [ Time Frame: Baseline to approximately 9 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San DiegoLa JollaCalifornia92093
Michael A Liss, MD, PhD
[email protected]
858-249-1240
Jessica Warbrick, ND
[email protected]
858-249-1240
Michael Liss, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in La Jolla, CA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
University of California, San Diego· La Jolla, CA

Related Studies